imatinib mesylate has been researched along with Angiogenesis, Pathologic in 70 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 37 (52.86) | 29.6817 |
| 2010's | 30 (42.86) | 24.3611 |
| 2020's | 3 (4.29) | 2.80 |
| Authors | Studies |
|---|---|
| Nathan, J; Palanivel, G; Shameera, R | 1 |
| Avsar, T; Ceylan, D; Kilic, T; Oksal, MD; Tatarli, N | 1 |
| Kaur, G; Piplani, H; Puri, S; Sanyal, SN; Vaish, V | 1 |
| Ghanghas, P; Kumar, K; Sanyal, SN | 1 |
| Cao, Y; Cimpean, AM; Deumelandt, KL; Griffioen, AW; Heldin, CH; Hendrix, MJ; Hosaka, K; Nowak-Sliwinska, P; Paulis, YW; Pauwels, P; Raica, M; Soetekouw, PM; Thijssen, VL; Tjan-Heijnen, VC; van den Oord, JJ | 1 |
| Cardenas, M; Cerchietti, L; Fan, L; Geng, H; Hajjar, KA; Leonard, JP; Luo, M; Melnick, A; Ruan, J; Wang, C; Yang, SN | 1 |
| Chute, JP; Himburg, HA | 1 |
| Andersson, P; Cao, Y; Feng, N; Hosaka, K; Jensen, L; Larsson, O; Li, X; Lim, S; Nakamura, M; Ohhashi, T; Rouhi, P; Seki, T; Xue, Y; Yang, X; Yang, Y | 1 |
| Aigner, A; Bakowsky, U; Özcetin, A | 1 |
| Cooke, VG; De Palma, M; Gu, C; Kalluri, R; Keskin, D; Kim, J; LeBleu, VS; Sugimoto, H; Wu, CC | 1 |
| Bobrzyk, M; Chronowska, J; Kukla, U; Madej, P; Okopień, B; Łabuzek, K | 1 |
| Ceelen, W; De Wever, O; Descamps, B; Gremonprez, F; Izmer, A; Vanhaecke, F; Vanhove, C | 1 |
| Ammendola, M; De Sarro, G; Gadaleta, CD; Leporini, C; Marech, I; Oakley, C; Ranieri, G; Russo, E; Sacco, R; Sammarco, G | 1 |
| Cao, H; Cao, XY; He, P; Jiang, SH; Li, Q; Li, RK; Tian, GA; Tu, L; Wang, Y; Yang, XM; Zhang, XX; Zhang, ZG; Zhu, CC; Zhu, L; Zhuang, C | 1 |
| Hu, Y; Jiang, T; Lu, H; Mei, H; Pang, Z; Shi, W; Wang, L; Zhang, B | 1 |
| Christiansson, L; Hjorth-Hansen, H; Loskog, A; Mustjoki, S; Olsson-Strömberg, U; Persson, I; Richter, J; Simonsson, B; Söderlund, S | 1 |
| Aftab, DT; Cornillie, J; Debiec-Rychter, M; Gebreyohannes, YK; Schöffski, P; Sciot, R; Van Looy, T; Vanleeuw, U; Vreys, L; Wellens, J; Wozniak, A | 1 |
| Angelini, S; Biasco, G; Gatto, L; Hrelia, P; Nannini, M; Pantaleo, MA; Ravegnini, G; Sammarini, G; Saponara, M; Simeon, V; Urbini, M; Venturoli, N; Zenesini, C | 1 |
| Aime, S; Cabodi, S; Consolino, L; Dastrù, W; Giovenzana, GB; Longo, DL; Sciortino, M | 1 |
| Malfertheiner, P; Treiber, G; Wex, T | 1 |
| Apel, A; Beckermann, BM; Büchler, MW; Büchler, P; Diehlmann, A; Friess, H; Frommhold, D; Giese, N; Groth, A; Herr, I; Ho, AD; Kallifatidis, G; Mattern, J; Moldenhauer, G; Saffrich, R; Salnikov, AV; Schubert, M; Wagner, W | 1 |
| Akhmetshina, A; Busch, N; Dees, C; Distler, JH; Distler, O; Gay, S; Jüngel, A; Maurer, B; Schett, G; Stürzl, M; Venalis, P; Zwerina, J | 1 |
| Albini, A; Ambrosini, C; Fassina, G; Ferrari, N; Frassoni, F; Monteghirfo, S; Pozzi, S; Soverini, S; Stigliani, S; Tosetti, F | 1 |
| Bran, B; Bran, G; Hörmann, K; Riedel, F | 1 |
| Gauthier, H | 1 |
| Bzyl, J; Fusenig, NE; Heusel, J; Kiessling, F; Lederle, W; Linde, N; Mueller, MM; Skobe, M; Woenne, EC; Zwick, S | 1 |
| Coelho, P; Costa, R; Pirraco, A; Rocha, A; Soares, R; Vasques, L | 1 |
| Dafni, H; Hu, S; Larson, PE; Ronen, SM; Venkatesh, HS; Vigneron, DB; Wang, C; Ward, CS; Yoshihara, HA; Zhang, X | 1 |
| Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
| Hoffman, R; Kiladjian, JJ; Mesa, RA | 1 |
| Chen, D; Chou, J; Falcon, BL; Hanahan, D; McDonald, DM; Pietras, K; Sennino, B | 1 |
| Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G | 1 |
| Blay, JY; Casali, PG; Cohen, DP; Demetri, GD; Garrett, CR; Goldstein, D; Harmon, CS; Huang, X; Hurwitz, HI; Le Cesne, A; Leyvraz, S; McArthur, GA; Paz-Ares, L; Pousa, AL; Schöffski, P; Shah, MH; Tassell, V; Verweij, J; Xu, QC | 1 |
| Chayama, K; Higashi, Y; Kitadai, Y; Ohara, E; Ohnishi, M; Onoyama, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
| Alessandro, R; Corrado, C; De Leo, G; Flugy, AM; Guggino, G; Karmali, R; Raimondo, S; Taverna, S | 1 |
| Edqvist, PH; Forsberg-Nilsson, K; Hallböök, F; Niklasson, M; Vidal-Sanz, M | 1 |
| Akgün, E; Avsar, T; Bayri, Y; Kılıç, T; Şeker, A; Yener, U | 1 |
| Jia, WD; Kong, LQ; Qian, YB; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Zhang, JB; Zhu, XD; Zhuang, PY | 1 |
| Akgun, E; Avsar, T; Baysal, K; Karal-Yilmaz, O; Kilic, T; Kukut, M; Ozkan, A | 1 |
| Bell, YC; Druker, BJ; Früh, K; Griffith, DJ; Heinrich, MC; Jarvis, MA; Luukkonen, BG; Moses, AV; Nelson, JA; Raggo, C; Ruhl, R; Wait, CL | 1 |
| Buchdunger, E; Dumont, D; Ebos, JM; Kerbel, RS; Master, Z; Melo, JV; Tran, J | 1 |
| Deininger, MW; Friedrich, T; Rumpel, M | 1 |
| George, D | 1 |
| Best, J; Cox, A; Dudley, A; Gilbert, RE; Jenkins, A; Price, JT; Thomas, D | 1 |
| Engels, K; Griesshammer, M; Klose, J; Kriener, S; Kvasnicka, HM; Schmitt-Graeff, A; Staib, P; Thiele, J | 1 |
| Engels, K; Kriener, S; Kvasnicka, HM; Schmitt-Graeff, A; Staib, P; Thiele, J | 1 |
| Ostman, A | 1 |
| Hanahan, D; Pietras, K | 1 |
| Gahmberg, CG; Kervinen, J | 1 |
| Fidler, IJ; Kim, SJ; Lev, DC; Nam, DH; Onn, A; Price, JE; Stone, V; Yazici, S | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Corcoran, NM; Costello, AJ | 1 |
| Aliberti, C; Benea, G; Conti, M; De Giorgi, U; Marangolo, M | 1 |
| Liu, YK; Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xu, Y; Ye, SL; Zhang, KZ; Zhang, T | 1 |
| Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S | 1 |
| Aramaki, H; Furuyama, A; Higuchi, S; Koyanagi, S; Nakagawa, H; Nakamura, M; Ohdo, S; Takiguchi, T | 1 |
| Dewhirst, MW; Herndon, JE; Rabbani, ZN; Vlahovic, G; Vujaskovic, Z | 1 |
| Chami, L; Lassau, N; Péronneau, P | 1 |
| Andrade-Gordon, P; Friedlander, M; Kurokawa, T; Mueller, BM; Ruf, W; Uusitalo-Jarvinen, H | 1 |
| Heldin, CH; Ostman, A | 1 |
| Daud, AI; Homsi, J | 1 |
| Bucana, C; Ellis, LM; Fan, F; Liu, W; McCarty, MF; Somcio, RJ; Stoeltzing, O; Wey, J | 1 |
| Bosch, J; Fernandez, M; Garcia-Pagan, JC; Garcia-Pras, E; Mejias, M; Mendez, R | 1 |
| Bergh, A; Johansson, A; Jones, J; Kilter, S; Pietras, K; Rudolfsson, SH; Skytt, A | 1 |
| Bergers, G; Hanahan, D; Pahler, J; Pietras, K | 1 |
| Fukumura, D; Jain, RK; Lahdenranta, J | 1 |
| Giordano, S; Petrelli, A | 1 |
| Bentley, B; Shao, R; Yan, W | 1 |
| Coleman, RL; Ellis, LM; Gershenson, DM; Jaffe, RB; Jennings, NB; Landen, CN; Langley, RR; Lin, YG; Lu, C; Merritt, WM; Sood, AK; Spannuth, W; Thaker, PH; Yancopoulos, GD | 1 |
| Buchdunger, E; Dal Cin, P; Dumanski, JP; Heldin, CH; O'Brien, KP; Ostman, A; Pietras, K; Shimizu, A; Sjöblom, T | 1 |
12 review(s) available for imatinib mesylate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Studying molecular signaling in major angiogenic diseases.
Topics: Angiogenesis Inhibitors; Bevacizumab; Cetuximab; Everolimus; Humans; Imatinib Mesylate; Neoplasms; Neovascularization, Pathologic; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2022 |
Targeting mast cells in gastric cancer with special reference to bone metastases.
Topics: Animals; Antigens, CD34; Benzamides; Benzamidines; Bone and Bones; Bone Neoplasms; Bone Resorption; Disease Progression; Gabexate; Guanidines; Humans; Imatinib Mesylate; Immune System; Mast Cells; Neovascularization, Pathologic; NF-kappa B; Piperidines; Proto-Oncogene Proteins c-kit; Pyridines; Stomach Neoplasms; Thiazoles; Tryptases | 2015 |
[Positron emission tomography and evaluation of response to targeted therapies].
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Hypoxia; Cell Proliferation; Choline; ErbB Receptors; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lipid Metabolism; Lung Neoplasms; Neoplasms; Neovascularization, Pathologic; Piperazines; Positron-Emission Tomography; Protein Biosynthesis; Protein Kinases; Pyrimidines; Radiopharmaceuticals; Receptors, Androgen; Receptors, Estrogen; TOR Serine-Threonine Kinases | 2009 |
The renaissance of interferon therapy for the treatment of myeloid malignancies.
Topics: Apoptosis; Benzamides; Cell Proliferation; Clinical Trials as Topic; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon Type I; Leukemia, Myeloid; Mastocytosis; Neoplastic Stem Cells; Neovascularization, Pathologic; Piperazines; Polycythemia Vera; Primary Myelofibrosis; Pyrimidines; Recombinant Proteins; Thrombocythemia, Essential | 2011 |
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Topics: Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Imatinib Mesylate; Leukemia; Ligands; Male; Models, Biological; Mutation; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Platelet-Derived Growth Factor | 2003 |
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.
Topics: Animals; Benzamides; Biological Transport; DNA Mutational Analysis; Fibroblasts; Humans; Imatinib Mesylate; Models, Biological; Mutation; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Stromal Cells | 2004 |
[Targeted anticancer drugs and their development].
Topics: Antineoplastic Agents; Benzamides; Cell Proliferation; Drug Delivery Systems; Female; Humans; Imatinib Mesylate; Male; Neoplasms; Neovascularization, Pathologic; Piperazines; Prognosis; Pyrimidines; Risk Factors; Treatment Outcome | 2004 |
[Tyrosine kinase inhibitors in tumor therapy--part 1. Molecular and genetic fundamentals].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Dimerization; Enzyme Activation; Growth Substances; Humans; Imatinib Mesylate; Neoplasms; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction | 2005 |
[Current events about echography in 2006: position of the ultrasound functional imaging for the early evaluation of targeted therapeutics].
Topics: Antineoplastic Agents; Benzamides; Contrast Media; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kidney Neoplasms; Microcirculation; Neoplasms; Neovascularization, Pathologic; Phospholipids; Piperazines; Polysaccharides; Pyrimidines; Sulfur Hexafluoride; Treatment Outcome; Ultrasonography | 2006 |
PDGF receptors as targets in tumor treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Extracellular Fluid; Fibroblasts; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pressure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sunitinib; Translocation, Genetic | 2007 |
Spectrum of activity and mechanism of action of VEGF/PDGF inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
1 trial(s) available for imatinib mesylate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
Topics: Adult; Aged; Benzamides; Biomarkers, Tumor; Cross-Over Studies; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Placebos; Pyrimidines; Pyrroles; Retreatment; Sunitinib; Survival Analysis; Young Adult | 2012 |
57 other study(ies) available for imatinib mesylate and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Antiangiogenic Molecules Suppressed Meningioma-Induced Neovascularization: A Corneal Angiogenesis Study.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Corneal Neovascularization; Imatinib Mesylate; Meningeal Neoplasms; Meningioma; Neovascularization, Pathologic; Rats; Receptor, Platelet-Derived Growth Factor beta; RNA | 2022 |
Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Membrane; Disease Models, Animal; Disease Progression; Female; Imatinib Mesylate; Inflammation; Lung Neoplasms; Membrane Potentials; Mitochondria; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Signal Transduction; Tumor Microenvironment | 2020 |
Chemopreventive action of Imatinib, a tyrosine kinase inhibitor in the regulation of angiogenesis and apoptosis in rat model of lung cancer.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; Female; Imatinib Mesylate; Inflammation; Lipopolysaccharides; Lung Neoplasms; Neoplasm Proteins; Neoplasms, Experimental; Neovascularization, Pathologic; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley | 2018 |
Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth.
Topics: Animals; Antineoplastic Agents, Immunological; Biological Mimicry; Cell Communication; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Humans; Imatinib Mesylate; Melanoma, Experimental; Mice; Mice, Nude; Neovascularization, Pathologic; Pericytes; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Apoptosis; Benzamides; Biomarkers, Tumor; Blotting, Western; Cell Differentiation; Cell Proliferation; Gene Expression Profiling; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Mice; Mice, SCID; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Pericytes; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured | 2013 |
Imatinib tackles lymphoma via the PDGFRβ+ pericyte.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Benzamides; Humans; Imatinib Mesylate; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Neovascularization, Pathologic; Pericytes; Piperazines; Pyrimidines | 2013 |
Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Becaplermin; Benzamides; Carcinoma, Lewis Lung; Cell Movement; Cell Proliferation; Fibrosarcoma; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Integrin alpha1beta1; Lung Neoplasms; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Gelatin; Gelatin Sponge, Absorbable; Image Interpretation, Computer-Assisted; Imatinib Mesylate; Mice; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2.
Topics: Angiopoietin-2; Animals; Antibodies; Antigens; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Female; Imatinib Mesylate; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Knockout; Neovascularization, Pathologic; Pericytes; Protein Kinase Inhibitors; Proteoglycans; Receptor, Platelet-Derived Growth Factor beta; Retina; Signal Transduction | 2015 |
[Antiangiogenic therapy of malignant pheochromocytoma and paraganglioma with the view to the recent scientific developments].
Topics: Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Benzamides; Humans; Imatinib Mesylate; Indoles; Neovascularization, Pathologic; Paraganglioma; Pheochromocytoma; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sunitinib; Thalidomide | 2015 |
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Extracellular Fluid; HT29 Cells; Humans; Imatinib Mesylate; Indazoles; Infusions, Parenteral; Mice; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Absorption; Peritoneum; Pressure; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays | 2015 |
CCBE1 promotes GIST development through enhancing angiogenesis and mediating resistance to imatinib.
Topics: Antineoplastic Agents; Calcium-Binding Proteins; Carcinogenesis; Cell Line, Tumor; Drug Resistance; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Male; Middle Aged; Neovascularization, Pathologic; Prognosis; Survival Analysis; Tumor Suppressor Proteins; Up-Regulation | 2016 |
Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Perfusion; Receptor, Platelet-Derived Growth Factor beta; Tumor Microenvironment | 2016 |
Plasma proteomics in CML patients before and after initiation of tyrosine kinase inhibitor therapy reveals induced Th1 immunity and loss of angiogenic stimuli.
Topics: Adult; Aged; Blood Proteins; Dasatinib; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Neovascularization, Pathologic; Pilot Projects; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Th1 Cells | 2016 |
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Biopsy; Cell Line, Tumor; Disease Models, Animal; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Necrosis; Neoplasm Grading; Neovascularization, Pathologic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.
Topics: Adult; Aged; Aged, 80 and over; Demography; Disease Progression; Female; Gastrointestinal Stromal Tumors; Genetic Association Studies; Genetic Predisposition to Disease; Haplotypes; Humans; Imatinib Mesylate; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neovascularization, Pathologic; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Time Factors; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-3; Young Adult | 2017 |
Assessing tumor vascularization as a potential biomarker of imatinib resistance in gastrointestinal stromal tumors by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Heterografts; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Mice; Neovascularization, Pathologic | 2017 |
Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Octreotide; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrimidines; Randomized Controlled Trials as Topic; Survival Analysis | 2009 |
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma.
Topics: Actins; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cell Differentiation; Cell Movement; Cell Proliferation; Cells, Cultured; Cetuximab; Endothelium, Vascular; Epidermal Growth Factor; Fibroblasts; Humans; Imatinib Mesylate; Lentivirus; Male; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Muscle, Smooth; Neovascularization, Pathologic; Pancreatic Neoplasms; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Spheroids, Cellular; Transplantation, Heterologous; Umbilical Veins; Vascular Endothelial Growth Factor A | 2008 |
Lack of inhibitory effects of the anti-fibrotic drug imatinib on endothelial cell functions in vitro and in vivo.
Topics: Animals; Apoptosis; Benzamides; Biomarkers; Blood Vessels; Cell Proliferation; Cell Survival; Chemotaxis; Endothelial Cells; Fibrosis; Humans; Imatinib Mesylate; Mice; Neovascularization, Pathologic; Piperazines; Pyrimidines; Reproducibility of Results | 2009 |
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Adhesion; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Endothelial Cells; Extracellular Matrix; Flavonoids; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Invasiveness; Neovascularization, Pathologic; NF-kappa B; Piperazines; Propiophenones; Pyrimidines; Reactive Oxygen Species; Tumor Suppressor Protein p53; U937 Cells; Vascular Endothelial Growth Factor A | 2008 |
The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; Female; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2009 |
Platelet-derived growth factor-B normalizes micromorphology and vessel function in vascular endothelial growth factor-A-induced squamous cell carcinomas.
Topics: Animals; Benzamides; Carcinoma, Squamous Cell; Cell Proliferation; Cells, Cultured; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neovascularization, Pathologic; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Transfection; Transplantation, Heterologous; Tumor Burden; Vascular Endothelial Growth Factor A | 2010 |
Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells.
Topics: Animals; Benzamides; Imatinib Mesylate; Melanoma, Experimental; Mice; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neovascularization, Pathologic; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Signal Transduction | 2010 |
Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor.
Topics: Animals; Benzamides; Capillary Permeability; Carbon Isotopes; Humans; Hypoxia-Inducible Factor 1; Imatinib Mesylate; L-Lactate Dehydrogenase; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2010 |
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Camptothecin; Cell Proliferation; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Benzamides; Benzimidazoles; Carcinoma, Lewis Lung; Cell Proliferation; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Imatinib Mesylate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Treatment Outcome | 2011 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Stroma-directed imatinib therapy impairs the tumor-promoting effect of bone marrow-derived mesenchymal stem cells in an orthotopic transplantation model of colon cancer.
Topics: Animals; Apoptosis; Benzamides; Bone Marrow Cells; Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colonic Neoplasms; Female; Humans; Imatinib Mesylate; Liver Neoplasms; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Piperazines; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Transplantation, Heterologous; Tumor Microenvironment | 2013 |
Carboxyamidotriazole-orotate inhibits the growth of imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Exosomes; Extracellular Signal-Regulated MAP Kinases; Fusion Proteins, bcr-abl; Gene Expression Regulation, Leukemic; Human Umbilical Vein Endothelial Cells; Humans; Imatinib Mesylate; Interleukin-8; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Neovascularization, Pathologic; Orotic Acid; Phosphorylation; Phosphotyrosine; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Triazoles; Xenograft Model Antitumor Assays | 2012 |
Platelet-derived growth factor over-expression in retinal progenitors results in abnormal retinal vessel formation.
Topics: Animals; Astrocytes; Benzamides; Biomarkers; Capillaries; Cell Death; Cell Lineage; Cell Movement; Cell Proliferation; Gene Expression; Humans; Imatinib Mesylate; Intraocular Pressure; Mice; Mice, Transgenic; Neovascularization, Pathologic; Neuroglia; Photoreceptor Cells, Vertebrate; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyrimidines; Retina; Retinal Vessels; Stem Cells; Time Factors; Transgenes | 2012 |
Assessment of antiangiogenic effect of imatinib mesylate on vestibular schwannoma tumors using in vivo corneal angiogenesis assay.
Topics: Animals; Antineoplastic Agents; Benzamides; Brain; Cornea; Cranial Nerve Neoplasms; Glioblastoma; Humans; Imatinib Mesylate; Male; Neovascularization, Pathologic; Neurofibromatosis 2; Neuroma, Acoustic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Platelet-Derived Growth Factor; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Up-regulation of platelet-derived growth factor-A is responsible for the failure of re-initiated interferon alpha treatment in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Retreatment; Reverse Transcriptase Polymerase Chain Reaction; Treatment Failure; Tumor Burden; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Controlled release of imatinib mesylate from PLGA microspheres inhibit craniopharyngioma mediated angiogenesis.
Topics: Antineoplastic Agents; Benzamides; Chromatography, High Pressure Liquid; Craniopharyngioma; Imatinib Mesylate; Lactic Acid; Microspheres; Neovascularization, Pathologic; Piperazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyrimidines; Spectrophotometry, Ultraviolet | 2013 |
Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells.
Topics: Base Sequence; Benzamides; Cell Adhesion; Cell Division; Cell Line; Cell Size; Cell Transformation, Neoplastic; Cell Transformation, Viral; DNA; Endothelium, Vascular; Gene Expression Profiling; Herpesvirus 8, Human; Humans; Imatinib Mesylate; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Proto-Oncogenes; Pyrimidines; Sarcoma, Kaposi; Signal Transduction; Stem Cell Factor; Up-Regulation | 2002 |
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Cell Division; Cells, Cultured; Culture Media, Conditioned; Densitometry; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Intercellular Signaling Peptides and Proteins; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphokines; Mice; Neovascularization, Pathologic; Piperazines; Precipitin Tests; Pyrimidines; Time Factors; Transfection; Umbilical Veins; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Imatinib normalizes bone marrow vascularity in patients with chronic myeloid leukemia in first chronic phase.
Topics: Benzamides; Blood Vessels; Bone Marrow; Case-Control Studies; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neovascularization, Pathologic; Piperazines; Pyrimidines | 2003 |
STI-571 inhibits in vitro angiogenesis.
Topics: Animals; Antineoplastic Agents; Benzamides; Cattle; Cells, Cultured; Chemotaxis; Endothelium, Vascular; Flow Cytometry; Imatinib Mesylate; In Vitro Techniques; Neovascularization, Pathologic; Phosphorylation; Piperazines; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta | 2003 |
Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy.
Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow; Bone Marrow Examination; Drug Evaluation; Humans; Hydroxyurea; Imatinib Mesylate; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microcirculation; Neovascularization, Pathologic; Piperazines; Pyrimidines; Recombinant Proteins; Remission Induction; Retrospective Studies | 2004 |
[Therapy-related changes of angiogenesis in Philadelphia chromosome positive chronic myelogenous leukemia].
Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Bone Marrow Transplantation; Humans; Imatinib Mesylate; Immunohistochemistry; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neovascularization, Pathologic; Piperazines; Pyrimidines; Reference Values | 2004 |
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Topics: Adenoma, Islet Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Clinical Protocols; Cyclophosphamide; Disease Models, Animal; Endothelial Cells; Imatinib Mesylate; Indoles; Mice; Mice, Transgenic; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sunitinib | 2005 |
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Platelet-Derived Growth Factor; Pyrimidines; Radiography; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Time Factors | 2005 |
Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Synergism; Fluorescent Antibody Technique; Imatinib Mesylate; Male; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Treatment Failure | 2005 |
Effect of angiosonography to monitor response during imatinib treatment in patients with metastatic gastrointestinal stromal tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Tomography, X-Ray Computed; Ultrasonography; Vascular Endothelial Growth Factor A | 2005 |
Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential.
Topics: Animals; Benzamides; Carcinoma, Hepatocellular; Cell Proliferation; Endothelium, Vascular; Gene Expression Profiling; Humans; Imatinib Mesylate; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neovascularization, Pathologic; Oligonucleotide Array Sequence Analysis; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Transcriptional Activation | 2005 |
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured | 2006 |
Basis for dosing time-dependent change in the anti-tumor effect of imatinib in mice.
Topics: Angiogenesis Inhibitors; Animals; Benzamides; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Imatinib Mesylate; Male; Mice; Mice, Inbred ICR; Neovascularization, Pathologic; Piperazines; Pyrimidines; Sarcoma 180 | 2006 |
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Extracellular Fluid; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Nude; Microscopy, Fluorescence; Models, Biological; Neovascularization, Pathologic; Oxygen; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Pressure; Pyrimidines; Random Allocation; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2006 |
Role of protease activated receptor 1 and 2 signaling in hypoxia-induced angiogenesis.
Topics: Animals; Benzamides; Blood Coagulation Factor Inhibitors; Cell Line, Tumor; Disease Models, Animal; Factor VIIa; Hyperoxia; Hypoxia; Imatinib Mesylate; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Neoplasms, Experimental; Neovascularization, Pathologic; Oxygen; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, PAR-1; Receptor, PAR-2; Retinal Neovascularization; Retinal Vessels; Signal Transduction; Thromboplastin; Time Factors | 2007 |
Overexpression of PDGF-BB decreases colorectal and pancreatic cancer growth by increasing tumor pericyte content.
Topics: Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Line, Tumor; Colorectal Neoplasms; DNA, Complementary; Gene Expression; Humans; Imatinib Mesylate; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Pericytes; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Transfection | 2007 |
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats.
Topics: Animals; Benzamides; Disease Models, Animal; Drug Therapy, Combination; Hypertension, Portal; Imatinib Mesylate; Immunosuppressive Agents; Ligation; Male; Mesenteric Artery, Superior; Neovascularization, Pathologic; Piperazines; Platelet-Derived Growth Factor; Portal Vein; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Signal Transduction; Sirolimus; Splanchnic Circulation; Vascular Endothelial Growth Factor A | 2007 |
A stroma targeted therapy enhances castration effects in a transplantable rat prostate cancer model.
Topics: Adenocarcinoma; Androgen Receptor Antagonists; Angiopoietins; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Down-Regulation; Drug Therapy, Combination; Imatinib Mesylate; Immunoglobulin Fc Fragments; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Orchiectomy; Piperazines; Prostate; Prostatic Neoplasms; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor beta; Receptor, TIE-2; Receptors, Androgen; Recombinant Fusion Proteins; Stromal Cells; Xenograft Model Antitumor Assays | 2007 |
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma; Epithelial Cells; Estradiol; Female; Fibroblast Growth Factor 2; Fibroblast Growth Factor 7; Fibroblasts; Human papillomavirus 16; Humans; Imatinib Mesylate; Mice; Mice, Inbred Strains; Mice, Transgenic; Neoplasm Proteins; Neovascularization, Pathologic; Paracrine Communication; Pericytes; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stromal Cells; Uterine Cervical Neoplasms | 2008 |
Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Fibroblasts; Imatinib Mesylate; Mice; Neoplasm Proteins; Neovascularization, Pathologic; Paracrine Communication; Pericytes; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Uterine Cervical Neoplasms | 2008 |
Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.
Topics: Angiogenesis Inducing Agents; Animals; Benzamides; Cell Line; Cell Proliferation; Cytoplasm; Cytoskeleton; Endothelial Cells; Enzyme Activation; Fibroblast Growth Factor 2; Humans; Imatinib Mesylate; Mice; Mice, SCID; Models, Biological; Mutant Proteins; Neoplasms; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-abl; Pyrimidines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Bevacizumab; Endothelial Cells; Female; Gene Expression; Imatinib Mesylate; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Pericytes; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2008 |
Growth inhibition of dermatofibrosarcoma protuberans tumors by the platelet-derived growth factor receptor antagonist STI571 through induction of apoptosis.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Division; Child, Preschool; Dermatofibrosarcoma; Female; Fibrosarcoma; Giant Cell Tumors; Growth Inhibitors; Humans; Imatinib Mesylate; Infant; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Skin Neoplasms; Xenograft Model Antitumor Assays | 2001 |